References
- Thompson MA , AbergJA, HoyJF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308 , 387–402 (2012).
- Sungkanuparph S , TechasathitW, UtaipiboonC et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 4 , 515–528 (2010).
- Shubber Z , CalmyA, Andrieux-MeyerI et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS doi:10.1097/QAD.0b013e32835f1db0 (2013) (Epub ahead of print).
- Marzolini C , TelentiA, DecosterdLA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15 , 71–75 (2001).
- Gounden V , van Niekerk C, Snyman T et al. Presence of the CYP2B6 516G>T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res. Ther.7 , 32 (2010).
- Kenedi CA , GoforthHW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav.15 , 1803–1818 (2011).
- Maimbo M , KiyotaniK, MushirodaT et al. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur. J. Clin. Pharmacol.68 , 267–271 (2012).
- Haas DW , RibaudoHJ, KimRB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study. AIDS 18 , 2391–2400 (2004).
- Sukasem C , CresseyTR, PrapaithongP et al. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br. J. Clin. Pharmacol. 74 , 1005–1012 (2012).
- Sukasem C , ChamnanpholM, KoomdeeN et al. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections. Drug Metab. Pharmacokinet. doi:http://dx.doi.org/10.2133/dmpk.DMPK-12-RG-120 (2013) (Epub ahead of print).
- Manosuthi W , SukasemC, LueangniyomkulA et al. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug–drug interaction on efavirenz levels in HIV/tuberculosis co-infected patients. Antimicrob. Agents Chemother. 57 , 1019–1024 (2013).
- Wyen C , HendraH, VogelM et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61 , 914–918 (2008).
- Fabbiani M , BraccialeL, RagazzoniE et al. Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure. Infection 39 , 563–569 (2011).
- Ståhle L , MobergL, SvenssonJO et al. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther. Drug Monit. 26 , 267–270 (2004).
- Gatanaga H , HayashidaT, TsuchiyaK et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45 , 1230–1237 (2007).